Literature DB >> 26115672

Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake.

Brian B Graham1, Rahul Kumar2, Claudia Mickael2, Linda Sanders2, Liya Gebreab2, Kendra M Huber3, Mario Perez2, Peter Smith-Jones4, Natalie J Serkova3, Rubin M Tuder2.   

Abstract

In severe pulmonary hypertension (SPH), prior studies have shown an increase in right ventricle (RV) uptake of glucose, but it is unclear whether there is a change in the relative utilization of fatty acids. We hypothesized that in the RV in SPH, as in left ventricular (LV) failure, there is altered substrate utilization, with increased glucose uptake and decreased fatty acid uptake. SPH was induced in rats by treatment with the VEGF receptor inhibitor SU5416 and 3 wk of hypoxia (10% FiO2 ), followed by an additional 4 wk of normoxia (SU-Hx group). Control rats were treated with carboxymethylcellulose vehicle and 7 wk of normoxia (CMC-Nx group). The rodents then underwent positron emission tomography with sequential administration of two radiotracers, 2-deoxy-2-[(18)F]fluoroglucose ((18)F-FDG) and 14-(R,S)-[(18)F]fluoro-6-thia-heptadecanoic acid ((18)F-FTHA), analogs of glucose and fatty acid, respectively. Five CMC-Nx and 3 SU-Hx rats completed the entire experimental protocol. In the RV, there was a mild increase in (18)F-FDG uptake (1.35-fold, P = 0.085) and a significant decrease in (18)F-FTHA uptake (-2.1-fold, P < 0.05) in the SU-Hx rats relative to the CMC-Nx rats. In the LV, SU-Hx rats had less uptake of both radiotracers compared with CMC-Nx rats. Less RV fatty acid uptake in SPH was corroborated by decreased fatty acid transporters and enzymes in the RV tissue, and specifically a decrease in lipoprotein lipase. In the RV in rats with SPH, there is a major shift in metabolic substrate preference, largely due to decreased fatty acid uptake.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  fatty acid oxidation; metabolism; pulmonary hypertension; right ventricle

Mesh:

Substances:

Year:  2015        PMID: 26115672      PMCID: PMC4556932          DOI: 10.1152/ajplung.00169.2015

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  23 in total

Review 1.  Myocardial substrate metabolism in the normal and failing heart.

Authors:  William C Stanley; Fabio A Recchia; Gary D Lopaschuk
Journal:  Physiol Rev       Date:  2005-07       Impact factor: 37.312

2.  Formation of plexiform lesions in experimental severe pulmonary arterial hypertension.

Authors:  Kohtaro Abe; Michie Toba; Abdallah Alzoubi; Masako Ito; Karen A Fagan; Carlyne D Cool; Norbert F Voelkel; Ivan F McMurtry; Masahiko Oka
Journal:  Circulation       Date:  2010-06-14       Impact factor: 29.690

3.  Increased right ventricular glucose metabolism in patients with pulmonary arterial hypertension.

Authors:  Mehmet Mustafa Can; Cihangir Kaymaz; Ibrahim Halil Tanboga; Hacer Ceren Tokgoz; Nesrin Canpolat; Erdem Turkyilmaz; Kenan Sonmez; Nihal Ozdemir
Journal:  Clin Nucl Med       Date:  2011-09       Impact factor: 7.794

4.  Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol.

Authors:  Minako Oikawa; Yutaka Kagaya; Hiroki Otani; Masahito Sakuma; Jun Demachi; Jun Suzuki; Tohru Takahashi; Jun Nawata; Tatsuo Ido; Jun Watanabe; Kunio Shirato
Journal:  J Am Coll Cardiol       Date:  2005-06-07       Impact factor: 24.094

Review 5.  Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions.

Authors:  W C Stanley; G D Lopaschuk; J L Hall; J G McCormack
Journal:  Cardiovasc Res       Date:  1997-02       Impact factor: 10.787

6.  The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle.

Authors:  Lin Piao; Yong-Hu Fang; Virgilio J J Cadete; Christian Wietholt; Dalia Urboniene; Peter T Toth; Glenn Marsboom; Hannah J Zhang; Idith Haber; Jalees Rehman; Gary D Lopaschuk; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2009-12-01       Impact factor: 4.599

7.  Comparison of fatty acid tracers FTHA and BMIPP during myocardial ischemia and hypoxia.

Authors:  B Renstrom; S Rommelfanger; C K Stone; T R DeGrado; K J Carlson; E Scarbrough; R J Nickles; A J Liedtke; J E Holden
Journal:  J Nucl Med       Date:  1998-10       Impact factor: 10.057

8.  Impaired regional fatty acid uptake and systolic dysfunction in hypertrophied right ventricle.

Authors:  N Nagaya; Y Goto; T Satoh; M Uematsu; S Hamada; S Kuribayashi; Y Okano; S Kyotani; Y Shimotsu; K Fukuchi; N Nakanishi; M Takamiya; Y Ishida
Journal:  J Nucl Med       Date:  1998-10       Impact factor: 10.057

9.  14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid (FTHA): evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids.

Authors:  T R DeGrado; H H Coenen; G Stocklin
Journal:  J Nucl Med       Date:  1991-10       Impact factor: 10.057

10.  Assessment of myocardial fatty acid metabolic abnormalities in patients with idiopathic dilated cardiomyopathy using 123I BMIPP SPECT: correlation with clinicopathological findings and clinical course.

Authors:  Y Yazaki; M Isobe; W Takahashi; H Kitabayashi; O Nishiyama; M Sekiguchi; T Takemura
Journal:  Heart       Date:  1999-02       Impact factor: 5.994

View more
  28 in total

Review 1.  The right ventricle and pulmonary hypertension.

Authors:  Mariëlle C van de Veerdonk; Harm J Bogaard; Norbert F Voelkel
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

2.  Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity.

Authors:  Quyen L Nguyen; Catherine Corey; Pamela White; Annie Watson; Mark T Gladwin; Marc A Simon; Sruti Shiva
Journal:  JCI Insight       Date:  2017-03-09

3.  Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

Authors:  Samar Farha; Didem Saygin; Margaret M Park; Hoi I Cheong; Kewal Asosingh; Suzy Aa Comhair; Olivia R Stephens; Emir C Roach; Jacqueline Sharp; Kristin B Highland; Frank P DiFilippo; Donald R Neumann; W H Wilson Tang; Serpil C Erzurum
Journal:  JCI Insight       Date:  2017-08-17

Review 4.  Update on novel targets and potential treatment avenues in pulmonary hypertension.

Authors:  John C Huetsch; Karthik Suresh; Meghan Bernier; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-02       Impact factor: 5.464

5.  Assessment of right ventricular metabolism: An emerging tool for monitoring pulmonary artery hypertension.

Authors:  Attila Feher; Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2016-11-18       Impact factor: 5.952

Review 6.  The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

Authors:  Thomas Bertero; Dror Perk; Stephen Y Chan
Journal:  Expert Opin Ther Targets       Date:  2019-05-11       Impact factor: 6.902

7.  Effects of an endothelin receptor antagonist, Macitentan, on right ventricular substrate utilization and function in a Sugen 5416/hypoxia rat model of severe pulmonary arterial hypertension.

Authors:  Katarzyna Drozd; Ali Ahmadi; Yupu Deng; Baohua Jiang; Julia Petryk; Stephanie Thorn; Duncan Stewart; Rob Beanlands; Robert A deKemp; Jean N DaSilva; Lisa M Mielniczuk
Journal:  J Nucl Cardiol       Date:  2016-09-29       Impact factor: 5.952

Review 8.  Metabolic syndrome, neurohumoral modulation, and pulmonary arterial hypertension.

Authors:  Bradley A Maron; Jane A Leopold; Anna R Hemnes
Journal:  Br J Pharmacol       Date:  2020-02-18       Impact factor: 8.739

9.  Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.

Authors:  Tim Lahm; Ivor S Douglas; Stephen L Archer; Harm J Bogaard; Naomi C Chesler; Francois Haddad; Anna R Hemnes; Steven M Kawut; Jeffrey A Kline; Todd M Kolb; Stephen C Mathai; Olaf Mercier; Evangelos D Michelakis; Robert Naeije; Rubin M Tuder; Corey E Ventetuolo; Antoine Vieillard-Baron; Norbert F Voelkel; Anton Vonk-Noordegraaf; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2018-08-15       Impact factor: 21.405

10.  Disease-specific platelet signaling defects in idiopathic pulmonary arterial hypertension.

Authors:  Kulwant S Aulak; Sami Al Abdi; Ling Li; Jack S Crabb; Arnab Ghosh; Belinda Willard; Dennis J Stuehr; John W Crabb; Raed A Dweik; Adriano R Tonelli
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-02-17       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.